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Treatment-Resistant Depression and Risk of
Suicide
PAUL N. PFEIFFER, MD, HYUNGJIN M. KIM, SCD, DARA GANOCZY, MPH, KARA ZIVIN,
PHD, AND MARCIA VALENSTEIN, MD
We evaluated whether treatment-resistant depression (TRD) as measured
by the Massachusetts General Hospital (MGH) staging method was associated
with suicide in a large U.S. health system. Data from the Veterans
Health Administration and the National Death Index were used to conduct a
case–control study of patients newly diagnosed with depression who received
antidepressant treatment between 2003 and 2006. Suicide cases (N = 499) were
matched with nonsuicide controls (N = 1994). Conditional logistic regression
was used to assess whether MGH stage at time of suicide (or matched date) was
associated with case status, adjusting for patient demographic characteristics,
comorbidity, and service use. Results indicated 11.6% of suicide cases had MGH
stage 3 or greater (indicating at least two antidepressant trials) compared to 6.4%
of controls (p < .001). In adjusted analyses, suicide was not significantly more
likely among patients with stage 3 or greater (OR 1.52; 95% CI: 0.98, 2.37) or
stages 1.5–2.5 (OR 1.19; 95% CI: 0.91, 1.55) compared to patients with stage 1
or less (<10 weeks of antidepressant medication). Staging TRD using MGH cri-
teria is unlikely to substantially improve suicide risk assessment of depressed
patients beyond existing measures contained in health system records.
Treatment-resistant depression (TRD) has
been broadly defined as a major depres-
sive disorder that fails to remit despite an
adequate course of antidepressant medica-
tion treatment (Berman, Narasimhan, &
Charney, 1997; Fava, 2003; Fornaro &
Giosue, 2010; Nelsen & Dunner, 1995;
Souery et al., 2007). TRD has been
reported to occur in at least one-third of
depressed patients and has been associated
with prolonged functional impairment,
earlier relapse if remission is eventually
achieved, and increased health care costs
compared to treatment responders (Fava
& Davidson, 1996; Gibson et al., 2010;
Rush et al., 2006). Whether TRD simi-
larly confers a greater risk of suicide has
important clinical and public health impli-
cations, particularly if these patients can
be proactively identified from health sys-
tem records.
Individuals with affective disorders
such as depression have a twofold to fourfold
increased risk of suicide compared to other
patients, but it remains difficult to predict the
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approximately 2% to 5% of those with affec-
tive disorders who will die by suicide (Bost-
wick & Pankratz, 2000; Ilgen et al., 2010).
Patient characteristics associated with an
increased risk of suicidal behavior among
depressed patients include a history of prior
suicide attempt, comorbid anxiety, and
comorbid alcohol-use disorders (Oquendo,
Currier, & Mann, 2006; Pfeiffer, Ganoczy, Il-
gen, Zivin, & Valenstein, 2009). Treatment
patterns may also identify subgroups of
depressed patients at greater risk for suicide;
for example, patients with a recent psychiatric
hospitalization are at nearly five times greater
risk than those receiving general depression
care (Valenstein et al., 2009). There have
been concerns that initiation of antidepressant
medication treatment may not only be a mar-
ker of suicide risk but may play a causal role
in increasing suicidal behaviors, particularly
among children and adolescents (Hammad,
Laughren, & Racoosin, 2006). However,
meta-analysis of randomized controlled trials,
population-level studies of suicide and antide-
pressant prescribing, and longitudinal follow-up
of mood disorder patients suggests antide-
pressant treatment does not play a causal role
with regard to suicide risk (Angst, Stassen,
Clayton, & Angst, 2002; Gibbons, Hur,
Bhaumik, & Mann, 2006; Khan, Khan,
Kolts, & Brown, 2003).
Patients who fail to respond to anti-
depressant treatment, however, may be at
greater risk for suicide. Patients with TRD
are more likely to report a prior suicide
attempt than treatment responders,
although suicide-related outcomes subse-
quent to the development of TRD are less
well understood (Malhi, Parker, Crawford,
Wilhelm, & Mitchell, 2005; Nelsen &
Dunner, 1995).
We sought to determine whether
patients who are identified as having TRD
based on the Massachusetts General Hospi-
tal (MGH) method have an increased risk of
suicide mortality. The MGH method is
calculated based on the number and adequacy
of antidepressant trials, augmentations, and
receipt of electroconvulsive therapy (ECT;
Fava, 2003). It can be used to measure TRD
along a continuum or to define important
treatment milestones, and the method has
been validated in clinical settings by predict-
ing continued nonremission from depression
(Gibson et al., 2010; Petersen et al., 2005;
Ruhe, van Rooijen, Spijker, Peeters, &
Schene, 2012). If TRD stages as measured by
the MGH method predict suicide, this could
potentially assist clinicians and health sys-
tems in identifying high-risk subgroups that
may benefit from additional services.
METHODS
Data Source
Patient data used in our analyses were
obtained from the Veterans Health Admin-
istration’s (VHA) National Registry of
Depression (NARDEP), which contains
inpatient and outpatient treatment records,
including diagnoses at clinical encounters,
pharmacy records, and demographic infor-
mation, on all patients receiving treatment
for depression within the VHA (Blow,
Owen, & Valenstein, 2003). Data on cause
of death were obtained from the National
Death Index (NDI), a high quality, national
mortality database suitable for research pur-
poses, which was merged with NARDEP
(Cowper, Kubal, Maynard, & Hynes, 2002).
Data were obtained from fiscal year 2003
through 2008. The study was conducted in
concordance with institutional review board
approval at the Veterans Affairs Ann Arbor
Health System.
Case–Control Patient Selection and
Matching
We used a case–control design to
assess differences in MGH stages of TRD
between patients who did or did not die by
suicide. The case–control design was chosen
to allow for variable follow-up periods to
measure TRD scores and covariates. To
ensure comparable starting points for TRD
measurement, cases and controls were
patients with new episodes of depression that
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included new antidepressant treatment. Spe-
cifically, patients had (1) an index depressive
disorder diagnosis (International Classification
of Diseases [ICD-9-CM] codes 293.83, 296.2x,
296.3x, 296.90, 296.99, 298.0, 300.4, 301.12,
309.0, 309.1, 311) at an outpatient clinical
encounter between fiscal years 2003 and
2006 without a depressive disorder diagnosis
in the prior 6 months, and (2) an index anti-
depressant prescription either 30 days prior
or 14 days after the index depressive disorder
diagnosis but otherwise with no antidepres-
sant treatment in the prior 6 months. We
excluded patients with a diagnosis of bipolar
disorder, schizophrenia, or schizoaffective
disorder in the 2 years following the index
diagnosis. Patients with a psychiatric hospi-
talization in the 6 months prior to the index
depression diagnosis were excluded to avoid
misclassifying outpatient depression treat-
ment as new when it began in the inpatient
setting.
Cases included all suicide deaths in
the 2 years following the initiation of anti-
depressant treatment and were identified
from the cause of death fields contained in
the NDI using the ICD-10 codes X60-X84
and Y87.0 [World Health Organization
(WHO), 2004]. We selected 2 years as the
follow-up period to allow adequate time to
measure treatment resistance while decreas-
ing the likelihood of measuring recurrent
episodes. For each case, up to four individ-
ually matched controls were randomly
selected from patients whose index antide-
pressant prescription occurred within 1
week of the case index antidepressant pre-
scription and who were still alive when the
case patient died by suicide. Case and con-
trols were further matched by gender and
age (within 5 years).
Measures
Treatment-resistant depression stage
and other patient characteristics potentially
associated with suicide risk were measured
from the index depression diagnosis or
index antidepressant fill, whichever came
first, to the time of suicide death (cases) or
matched time period (controls). Thus, mea-
surement periods varied across cases but
were equivalent (within 1 week) between
cases and their matched controls. TRD was
measured using the MGH method (Fava,
2003). Patients received 1 point for each
antidepressant medication for which they
obtained at least a 6-week supply with at
least one refill. Patients who never met these
criteria for any antidepressant received a 0.
For each antidepressant medication meeting
these initial criteria, patients received an
additional 0.5 points each if they received at
least a 10-week continuous supply of the
antidepressant medication or received the
maximum dose for at least 6 weeks. To
meet duration criteria, patients were
required to refill their medications such that
their supply on hand was not less than 80%
of a continuous supply. Although not speci-
fied in the initial description of the MGH
method, 80% is a validated cutoff for ade-
quate medication coverage in psychiatric
populations (Valenstein et al., 2002).
An additional 0.5 points was given if any of
the following augmentation agents were
added to an antidepressant: buspirone, lith-
ium, a stimulant, an atypical antipsychotic,
or a second antidepressant. Patients who
received electroconvulsive therapy received
an additional 3 points. To facilitate clinical
interpretation, we constructed three MGH
stage categories a priori based on clinical
relevance and previously established cutoffs
(Gibson et al., 2010): MGH stages 0 and 1
were combined to represent a subadequate
antidepressant trial (e.g., no antidepressant
trial reached 10 weeks duration or longer);
MGH stages 1.5–2.5 were combined to rep-
resent adequate (e.g., 10 weeks duration or
longer) to optimal treatment (e.g., maxi-
mum dose with augmentation) with an
initial antidepressant, while stages 3 and
above were combined because these stages
typically represent two or more adequate
antidepressant medication trials. MGH
stages of 3 or more generally represent the
presence of TRD when comparing to
dichotomous paradigms (Gibson et al.,
2010).
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Demographic characteristics in addition
to age and gender (for matching) included
marital status, Hispanic ethnicity, and race
(White, Black, Other, Unknown). “Other”
race includes patients of Asian, Native Hawai-
ian, Pacific Islander, or Native American race/
ethnicity, and patients who are multiracial.We
also included the region of the United States
where the patient received most of their care
(West,Northeast, UpperMidwest, South).
We measured patient characteristics
available in the administrative data that
have previously been associated with suicide
or that might confound the relationship
between antidepressant use and suicide
(Pfeiffer et al., 2009; Zivin et al., 2007).
Clinical diagnoses based on ICD-9-CM
codes entered at provider encounters were
used to determine whether patients received
a diagnosis of major depressive disorder
(ICD-9-CM codes 296.2x, 296.3x) versus
other depressive disorder diagnoses prior to
suicide. Comorbid psychiatric conditions
were similarly assessed, including posttrau-
matic stress disorder (PTSD), other anxiety
disorders (i.e., generalized anxiety disorder,
panic disorder, social phobia, anxiety disor-
der not otherwise specified), any substance
use disorder, and any personality disorder.
Prescription of any benzodiazepine medica-
tion during the follow-up period was deter-
mined from outpatient pharmacy records as
this is likely an indicator of undiagnosed
but significant comorbid anxiety symptoms
and is associated with suicide mortality
among depressed VHA patients (Pfeiffer
et al., 2009). Prescription of benzodiaze-
pines is not included in MGH staging.
General medical comorbidity was deter-
mined using a modified Charlson Comor-
bidity Index score greater than 0 (Quan
et al., 2005). The Charlson Comorbidity
Index is scored based on the presence of 17
different medical conditions and is associ-
ated with mortality (Charlson, Pompei,
Ales, & MacKenzie, 1987). We also mea-
sured any psychiatric hospitalization, and
total outpatient mental health encounters
subsequent to the index depression diagno-
sis or antidepressant fill.
Analyses
We tested for differences in patient
characteristics, including the mean MGH
stage and MGH stage categories between
cases and controls using generalized linear
models accounting for clustering within
matched sets of cases and controls. We then
conducted a conditional logistic regression
model to predict case status using MGH
category dummy variables as primary predic-
tors. The model included all demographic
characteristics, comorbidities, and mental
health service use variables as covariates. To
further assess the role of an MDD diagnosis
as a confounder, we constructed two addi-
tional post hoc case–control samples: one
including patients with an MDD diagnosis
and another of patients with depressive
disorder diagnoses other than MDD. We
included three additional years of data in
each sample to maintain statistical power
similar to the main analyses. We repeated
the above conditional logistic regression
analyses in both samples. Alpha was set at
0.05 for all comparisons. All analyses were
conducted in SAS version 9.3.
RESULTS
Among patients with new episodes of
antidepressant treatment for depression, we
identified 499 cases of suicide within
2 years of their index antidepressant fill and
matched these cases to 1994 controls.
Among cases, the mean time from index
antidepressant fill to suicide was 327 (SD
213) days. Consistent with a sample drawn
from the VHA veteran population, the
mean age was 56 years old, and 97% of
patients were male. In unadjusted analyses,
there were statistically significant differ-
ences in all measured variables between
cases and controls except for U.S. region
and comorbid PTSD (Table 1).
Suicide cases had a mean MGH stage
of 1.43 compared to 1.13 for controls
(p < .001). Among cases, 11.6% had an
MGH stage of 3 or greater compared to
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6.4% of controls (p < .001). MGH stage of
3 or greater indicated receipt of at least two
adequate antidepressant trials. MGH stage
greater than 5, generally indicating three or
more antidepressant trials, occurred in <1%
of the total sample (1.8% of cases and 0.6%
of controls). The maximum MGH stage,
reached by a single suicide case patient, was
9. Case patients compared to controls were
more likely to receive each individual com-
ponent of the MGH staging algorithm,
including 6 weeks of an antidepressant
medication (71.9% vs. 65.3%; p < .01),
10 weeks of an antidepressant medication
(58.1% vs. 52.8%; p = .02), maximum anti-
depressant dose (12.2% vs. 7.2%; p < .001),
an augmentation agent (22.4% vs. 11.9%;
p < .001), and ECT (0.40% vs. 0.05%;
p = .09), although the difference in ECT
was not statistically significant.
In analyses adjusted for demographic
and clinical characteristics, neither MGH
stage of 3 or more (OR 1.52; 95% CI: 0.98,
2.37) nor stage 1.5–2.5 (OR 1.19; 95% CI:
0.91, 1.55) was associated with case status
compared to stage 1 or less. Comorbid sub-
stance use disorders (OR 2.06; 95% CI:
1.52, 2.77), personality disorders (OR 1.70;
95% CI: 1.00, 2.87), benzodiazepine use
(OR 2.55; 95% CI: 1.96, 3.33), major
depressive disorder diagnosis (OR 1.65;
95% CI: 1.27, 2.12), and psychiatric hospi-
talization (OR 3.33; 95% CI: 2.34, 4.76)
were associated with an increased risk of
suicide. Comorbid PTSD (OR 0.63; 95%
CI: 0.45, 0.88), Black race (OR 0.21; 95%
CI: 0.12, 0.37), and being married (OR
0.56; 95% CI: 0.44, 0.71) were associated
with decreased risk of suicide. In unadjusted
analyses of samples restricted to patients
with or without an MDD diagnosis, MGH
stage 3 or greater was associated with
suicide among patients with an MDD diag-
nosis (OR 1.73; 95% CI: 1.21, 2.47) but
not among patients with other depressive
disorder diagnoses (OR 1.42; 95% CI: 0.88,
2.29). In adjusted analyses, MGH stage 3 or
greater was not associated with suicide for
patients with an MDD diagnosis (OR 1.14;
95% CI: 0.63, 1.24) or those with other
depressive disorder diagnoses (OR 1.26;
95% CI: 0.67, 2.35).
DISCUSSION
Although a depressive disorder diagno-
sis is a well-established risk factor for suicide,
suicide among depressed patients still remains
a rare event at less than 100 suicide deaths per
100,000 person years (Arsenault-Lapierre,
Kim, & Turecki, 2004; Ilgen et al., 2010;
Zivin et al., 2007). Further risk stratification
is therefore needed to identify depressed
patients at greatest risk who may benefit from
additional suicide prevention interventions.
This study found that TRD, as measured by
an MGH stage of 3 or more, was more com-
mon among patients who died by suicide than
matched nonsuicide controls, but MGH stage
3 or more was not a significant predictor of
suicide after adjusting for other known risk
factors.
Prior studies have evaluated suicide
risk (e.g., recent suicidal ideation or a his-
tory of suicide attempt) among those with
TRD (Malhi et al., 2005; Nelsen &
Dunner, 1995; Souery et al., 2007); however,
this is the first study to our knowledge that
has assessed a method for measuring TRD
among patients who have died by suicide.
MGH stage was associated with suicide in
unadjusted but not adjusted analyses, sug-
gesting that the constructs measured by the
MGH method overlap with other indicators
of illness severity included in the regression
model, such as a major depressive disorder
diagnosis or psychiatric hospitalization. It is
important to note that this study does not
negate the potential association between
TRD and increased suicide risk, particularly
among patients with a major depressive dis-
order diagnosis, but it does show that TRD
as measured by MGH method is not inde-
pendently associated with increased risk.
TRD staging may also be sensitive to a
heterogeneous group of unmeasured under-
lying constructs, of which only some may
be related to suicide, thereby diminishing
the association between broad measures of
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TRD and suicide. Potential such contribu-
tors to TRD include genetically mediated
pathophysiologic subtypes of depression,
brain changes following under treatment of
chronic early life depression and differences
in drug metabolism and pharmacodynamics
(Bertilsson, 2007; Greden, Riba, & McIn-
nis, 2011; Judd et al., 2000; McMahon
et al., 2006; Nierenberg, 2003; Van, Schoe-
vers, & Dekker, 2008). Erroneous or arti-
factual progression to advanced stages of
TRD as measured by the MGH method
could also occur due to misdiagnosis or by
patient behaviors that lead to greater anti-
depressant prescribing independent of
actual treatment resistance (e.g., lower tol-
erance for mild symptoms, greater self-
advocacy) (Nelsen & Dunner, 1995).
Further study is needed to determine the
relative contribution of the above factors to
TABLE 1
Characteristics of Suicide Cases and Matched Controlsa among Veterans Health Administration
Patients with New Episodes of Antidepressant Treatment for Depression
Variable
Suicide Cases
(N = 499)
%
Matched Controls
(N = 1994)
% p Valueb
MGH Stage of TRD
Continuous Stage, M (SD) 1.43 (1.29) 1.13 (1.06) <.001
Categorical Stage, % <.001
Stage 0–1 39.1 45.6
Stage 1.5–2.5 49.3 47.9
Stage  3 11.6 6.4
Demographic characteristics
Age, M (SD) 55.9 (14.2) 56.0 (13.9) matched
Male sex, % 96.8 96.9 matched
Race, % <.001
White 73.0 72.7
Black 3.6 13.8
Other 1.8 3.0
Unknown 21.6 10.6
Hispanic ethnicity, % 3.4 5.2 <.001
Married, % 37.9 54.2 <.001
U.S. region, % .28
Northeast 17.8 17.1
Upper Midwest 25.1 23.2
West 21.8 19.6
South 35.3 40.1
Clinical factors
Major depressive disorder, % 44.9 30.3 <.001
Posttraumatic stress disorder, % 16.4 19.9 .08
Other anxiety disorder, % 29.1 18.7 <.001
Benzodiazepine prescription, % 43.1 22.0 <.001
Substance use disorder, % 35.7 19.2 <.001
Personality disorder, % 8.6 2.9 <.001
Charlson comorbidity index > 0, % 41.1 46.9 <.001
Psychiatric hospitalization, % 23.7 7.1 <.001
Outpatient mental health visits, M (SD) 8.2 (15.2) 6.4 (19.7) <.01
aMatched on age, gender, and time from index antidepressant fill.
bGeneral linear model accounting for clustering between matched sets of cases and controls.
PFEIFFER ET AL. 361
TRD and their independent associations
with suicide.
The associations between patient
characteristics other than MGH stage (e.g.,
race, comorbid substance use disorders) and
suicide are largely consistent with prior
studies of suicide risk among VHA patients,
although the case and control patients in
this study were drawn from a cohort that
overlaps with the cohorts used in these
prior studies (Pfeiffer et al., 2009; Zivin
et al., 2007). The decreased risk for suicide
associated with PTSD among depressed
patients may be counter-intuitive, but prior
VHA studies suggest patients with PTSD
have a lower suicide risk than patients with
depression (Desai, Dausey, & Rosenheck,
2005; Ilgen et al., 2010). PTSD comorbid
with depression may mitigate the risk asso-
ciated with depression rather than have an
additive effect. The availability of special-
ized treatment programs for PTSD and
compensation for PTSD service-connected
disabilities could also contribute to this
finding (Zivin et al., 2007).
Our finding regarding the prevalence
of TRD (MGH stage 3 or more) at 11.6% of
suicide cases is in contrast to the greater than
30% prevalence reported in other settings
(Fava & Davidson, 1996; Rush et al., 2006;
Souery et al., 2007). The lower prevalence
could relate to the case–control study design,
such that among suicide cases, treatment was
cut short by suicide and therefore the course
of depression treatment was not long enough
to demonstrate TRD; however, the mean
time to suicide of 327 days was sufficient for
a large majority of patients to undergo a sec-
ond antidepressant trial. Alternatively, the
lower prevalence of TRD likely relates to
differences in depression treatment in
routine clinical settings such as the VHA
compared to care delivered to clinical
research participants in prior studies. In rou-
tine practice, patients may be less likely to
persist in treatment beyond an initial antide-
pressant trial, and clinicians may not be as
vigilant or supported in recognizing TRD
and advancing beyond initial treatment
plans. Unusually high remission rates to
depression treatment as an explanation for
low TRD prevalence are unlikely based on
high comorbidity rates and clinical trial
experience in the VHA (Mohr et al., 2011).
Our study demonstrates the feasibility
of applying the MGH method to health
system administrative data sets. Additional
studies based on the MGH scoring algo-
rithm could adjust the relative weights of
initial antidepressant trials, augmentations,
TABLE 2
MGH Stage as a Predictor of Suicide Cases
(N = 499) versus Nonsuicide Controls
(N = 1,994) among Patients with Depression
Matched on Age, Gender, and Time from
Initiation of Antidepressant Treatment
Variable
AORa
(95% CI)
MGH Stage, vs. 1 or less
1.5–2.5 1.19 (0.91, 1.55)
3 or more 1.52 (0.98, 2.37)
Demographic characteristics
Race, vs. White
Black 0.21 (0.12, 0.37)
Other 0.92 (0.42, 2.02)
Hispanic ethnicity 1.03 (0.57, 1.88)
Married 0.56 (0.44. 0.71)
U.S. Region, vs. West
Northeast 1.14 (0.78, 1.65)
South 0.82 (0.59, 1.12)
Upper Midwest 1.08 (0.76, 1.53)
Additional clinical characteristics
Major depressive
disorder
1.64 (1.27, 2.12)
Posttraumatic stress
disorder
0.63 (0.45, 0.88)
Other anxiety disorder 1.14 (0.85, 1.54)
Benzodiazepine
prescription
2.55 (1.96, 3.33)
Substance use disorder 2.06 (1.52, 2.77)
Personality disorder 1.70 (1.00, 2.87)
Charlson comorbidity > 0 0.80 (0.62, 1.02)
Psychiatric hospitalization 3.33 (2.34, 4.76)
Outpatient mental
health visits
1.00 (0.99, 1.00)
Note. Bolded values are where the confi-
dence interval (95% CI) does not cross 1.0.
aAdjusted odd ratios (AOR) from condi-
tional logistic regression model including all
variables simultaneously.
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dose optimizations, and ECT to potentially
improve the algorithm’s predictive ability.
Although less than 1% of patients received
ECT, adjustments to the algorithm might
also consider excluding ECT for severe or
high-risk depression in the absence of prior
treatment failures.
Very large data sets are necessary to
study rare events such as suicide death.
However, these data sets are limited in that
they do not contain measures of depression
symptom severity or remission status. Our
findings are also limited in that diagnoses of
depression were made clinically as opposed
to the use of standardized, structured inter-
views, and we are unable to account for
depression treatments that occurred prior to
or outside of VHA services. We do note
that only 20% of VHA patients who also
use non-VA services receive mental health
care in both settings, and dual use is not
associated with differences in depression
symptoms (Liu et al., 2009). Medication use
was also measured from pharmacy refills,
which may be different than patients’ actual
ingestion of medication. However, we did
require patients to refill their medications
within time frames consistent with adequate
adherence. Finally, differences between the
VHA patient population and other depressed
patient populations may limit generalizabil-
ity.
CONCLUSION
We applied the MGH method for
staging TRD to health system records and
found that TRD stage was not associated
with suicide after adjusting for patient
demographic and other clinical character-
istics. Future work should examine the
various factors that contribute to TRD
and their associations with suicide inde-
pendent of other measures of depression
severity. Whether TRD is broadly associ-
ated with suicide could be further
explored through testing optimizations of
the MGH method or alternative TRD
staging methods.
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